News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Vivek Subbiah: Designing Clinical Trials for Patients With Rare Cancers
Vivek Subbiah/LinkedIn
May 21, 2025, 11:58

Vivek Subbiah: Designing Clinical Trials for Patients With Rare Cancers

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared an article on LinkedIn:

“On Clinical Trials Day thrilled to share our American Society of Clinical Oncology, ASCO Education Handbook article free online version.
“Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras”
  • The rare cancer research landscape is rapidly evolving with innovative trial designs and precision medicine approaches.
  • Though rare cancers (<150 cases per million annually) individually uncommon, they collectively represent a significant portion of all cancer diagnoses.
  • Next-gen sequencing has revolutionized this field alongside the development of tumor-agnostic therapies (BRAF/NTRK/RET inhibitors, immunotherapy for MSI-high cancers).
  • Collaborative initiatives & patient centric trials are expanding access.“

Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.

Authors: Vivek Subbiah, Megan Othus, Jim Palma, Branko Cuglievan, and Razelle Kurzrock.

You can read the full article on Journal of ASCO Educational Book.

Vivek Subbiah: Designing Clinical Trials for Patients With Rare Cancers

More posts featuring Vivek Subbiah.

American Society of Clinical Oncology ASCO Education Handbook ASCO25 Branko Cuglievan cancer Cancer research clinical trials Clinical Trials Day fight against cancer Global fight against cancer immunotherapy Jim Palma Megan Othus OncoDaily Oncology Rare Cancers Razelle Kurzrock Sarah Cannon Research Institute Vivek Subbiah
Special Coverage
Blog
May 21, 2025, 13:24
Dégi László Csaba: The European Commission Initiative on Cervical Cancer Working Group meeting at IARC
Insight
May 21, 2025, 13:17
Chris Boshoff: Pfizer Enters Licensing Agreement with 3SBio for Next-Gen Bispecific Antibody
Blog
May 21, 2025, 13:15
Lacy Hubbard: Elekta Foundation’s Progress Toward Cervical Cancer Elimination in Rwanda
Blog
May 21, 2025, 13:04
Call on Congress to Support Cancer Research - AACR
Blog
May 21, 2025, 12:59
E-Cigarette and Vaping Practices among U.S. Millennial Adults - Mount Sinai Department of Medicine
Oncolibrary
May 21, 2025, 12:55
Immunohistochemistry (IHC): How Antibodies Help Diagnose and Classify Disease
Blog
May 21, 2025, 12:50
Ahmed Magdy Rabea: Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma
Blog
May 21, 2025, 12:38
Heidi Ko: The Importance of Biomarker Testing HER2 in Cancer Care
Blog
May 21, 2025, 12:32
Oliver Bogler: NanCI Webapp to Support Scientists Using AI
Blog
May 21, 2025, 12:22
Vivek Subbiah: Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer
Blog
May 21, 2025, 12:16
Teresa Amaral: Honoring Clinical Research Teams on International Clinical Trials Day
Science
May 21, 2025, 12:14
Myeloma Paper of the Day, May 21st, suggested by Robert Orlowski